Monitor the November 16, 2026 interim payment deadline and the receipt of the GPCR waiver and release, which are key closing conditions. If the deal closes, Exicure will have ~$4.8M in cash but no operating assets, increasing the likelihood of a reverse merger or liquidation. Failure to close could leave Exicure with ongoing liabilities and no clear path forward.
Drug in focus
XCUR drug pipeline →GPC-100
◆ Mixed Named in this 8-K- Impact
- Phase
- Phase 2
- Time to market
- No timeline is estimable. The drug is still at Phase 2 with no announced Phase 3 plan under Exicure. The program is being sold to GPCRT Inc., making any go-to-market timeline dependent on the buyer's development strategy.
- Next catalyst
- None dated
What to watchWatch the November 16, 2026 interim payment deadline (KRW 2.0 billion) as a sign of deal commitment from GPCRT Inc., and the November 30, 2026 expected closing. If the deal closes, Exicure will have ~$4.8M cash but no operating assets. If it fails, Exicure faces a severe liquidity crunch with no pipeline and an active Nasdaq delisting notice.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 10 $1.08entry
- T+1 · 6d ago +2.78%α +1.46% · $1.11
- T+4 · todayOpen
- T+5 · in 8h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Exicure agreed to sell its GPC-100 (burixafor) program assets to GPCRT Inc. for KRW 6.5 billion (approximately US$4.8 million) in cash. The deal includes the license agreement, contracts, IP, clinical data and equipment, while Exicure retains its subsidiary GPCR USA and all pre-September 1, 2026 liabilities. The transaction is subject to closing conditions including a GPCR waiver and potential stockholder approval, and is part of Exicure's strategic alternatives review.
Key Financial Metrics
Key Facts
- Aggregate purchase price of KRW 6.5 billion (approximately US$4.8 million), payable entirely in cash
- KRW 500 million deposit already paid; KRW 2.0 billion due on or before November 16, 2026; KRW 4.0 billion due at closing
- Closing date is November 30, 2026, subject to satisfaction of conditions including GPCR waiver and release, regulatory approvals, third-party consents, and any required stockholder approval
- GPCR USA remains a wholly owned subsidiary of Exicure after closing; no equity interests are being transferred
- Purchaser assumes future milestone and royalty obligations under the License Agreement, plus program costs from September 1, 2026 onward
- Exicure retains all pre-September 1, 2026 GPC-100 program liabilities, including unpaid CRO fees of US$644,383.49 and sublease obligations of US$782,897.71
- 90% of purchase price allocated to rights under the License Agreement; 10% to assigned contracts and other assets; 0% to IP and goodwill
- Company market cap is $6M; the $4.8M deal value represents approximately 80% of market cap
Financial Impact
Cash inflow of KRW 6.5 billion (approx. US$4.8 million) to Exicure, representing ~80% of its $6M market cap. Exicure sheds future GPC-100 development costs but retains significant pre-close liabilities.
Risk Factors
- Closing conditions may not be satisfied, including GPCR waiver, third-party consents, and potential stockholder approval
- Purchaser may fail to make the interim or final payments when due
- Exicure retains significant pre-September 1, 2026 liabilities including $644K in unpaid CRO fees and $783K in sublease obligations
- Following the sale, Exicure will have limited or no operating business, raising going concern and Nasdaq listing risks
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-455339 |
| Document: xcur-20261104.htm | 0001193125-26-455339 |
| Document: xcur-ex99_1.htm | 0001193125-26-455339 |
| Document: 0001193125-26-455339-index-headers.html | 0001193125-26-455339 |
| Document: 0001193125-26-455339-index.html | 0001193125-26-455339 |
| Document: 0001193125-26-455339.txt | 0001193125-26-455339 |
Track record
9 reports on XCUR
1 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +40.56% at T+60 after the Mar 25, 2026 report. 2 of 3 went positive at some point.
Filters
- Nov 16, 2026today Press Release Bearish 5/10 Entry $1.07 Now $1.07 −0.00% settles Nov 18
- Nov 12, 20264d ago DEF 14A Bearish 6/10 Entry $1.06 to $1.08 Now $1.07 −0.94% ▼ −1.89% −2.25% vs SPY
- Nov 10, 20266d ago 8-K Neutral 5/10 Viewing Entry $1.08 to $1.11 Now $1.07 −0.93% ▲ +2.78% +1.46% vs SPY
- Sep 16, 20268w ago 8-K Bearish 7/10 Entry $1.33 to $1.35 Now $1.07 +19.55% ▼ −1.50% −0.37% vs SPY
- Jun 30, 202619w ago 8-K Neutral 2/10 Entry $2.08 to $1.98 Now $1.07 −48.56% ▼ −4.81% −4.67% vs SPY
- Jun 1, 202624w ago Press Release Neutral 4/10 Entry $3.11 to $3.16 Now $1.07 −65.59% ▲ +1.61% +2.30% vs SPY
- Jun 1, 202624w ago 8-K Neutral 3/10 Entry $3.33 to $3.11 Now $1.07 −67.87% ▼ −6.61% −6.75% vs SPY
- Apr 10, 202631w ago 8-K Neutral 3/10 Entry $3.85 to $3.79 Now $1.07 −72.19% ▼ −1.56% −2.77% vs SPY
- Mar 25, 202633w ago Press Release Bearish 8/10 Entry $4.61 to $4.42 Now $1.07 +76.79% ▲ +4.23% +2.55% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers